MPM Oncology Impact Management »

Engene Holdings shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Engene Holdings (ENGN) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Engene Holdings

Tip: Access up to 7 years of quarterly data

All positions including Engene Holdings held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Engene Holdings by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $3.6M 530k 6.83

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Engene Holdings

Fcpm Iii Services B.v.
VR Adviser
Kynam Capital Management
Blue Owl Capital Holdings
Cormorant Asset Management
Braidwell
Deep Track Capital
Perceptive Advisors
Point72 Asset Management
Frazier Life Sciences Management
Franklin Resources
Adage Capital Partners GP
Sr One Capital Management
MPM Oncology Impact Management
Omega Fund Management

View all funds holding Engene Holdings